English
简体中文
Total: £ 56.28
Published Date: 2025-07-21 | Pages: 101 | Tables: 100 | Pharma & Healthcare
The global market for Biological Inactivated Vaccine was valued at US$ 892 million in the year 2024 and is projected to reach a revised size of US$ 1263 million by 2031, growing at a CAGR of 5.1% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Biological Inactivated Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Inactivated biological vaccines refer to a type of vaccine that uses physical or chemical methods (such as heat treatment, formaldehyde, β-propiolactone, etc.) to completely kill pathogenic microorganisms (such as viruses, bacteria, etc.), making them lose their infectivity and pathogenicity, while retaining their main antigenic structure to induce the body to produce a specific immune response. This type of vaccine is highly safe and suitable for people with weak immunity. It is widely used to prevent hepatitis A, polio, rabies, new coronavirus and other infectious diseases.
North American market for Biological Inactivated Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Biological Inactivated Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Biological Inactivated Vaccine include Sanofi, GSK, Merck, Pfizer, SII, Valneva, Bharat Biotech, KM Biologics, Baxter, Bio Farma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biological Inactivated Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Inactivated Vaccine.
The Biological Inactivated Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biological Inactivated Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, by Dosage Form and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biological Inactivated Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Dosage Form and by regions.
By Company
Sanofi
GSK
Merck
Pfizer
SII
Valneva
Bharat Biotech
KM Biologics
Baxter
Bio Farma
IVAC
Takeda
Emergent BioSolutions
Sinergium Biotech
China Biotechnology
Sinovac
Kangtai Biological
Zhifei Biological
AIM Vaccine
Segment by Type
Inactivated Virus Vaccine
Inactivated Bacterial Vaccine
Segment by Dosage Form
Liquid Vaccines
Freeze-Dried Vaccines
Segment by Application
Humans
Animals
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biological Inactivated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biological Inactivated Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Biological Inactivated Vaccine Market Overview
1.1 Product Definition
1.2 Biological Inactivated Vaccine by Type
1.2.1 Global Biological Inactivated Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Inactivated Virus Vaccine
1.2.3 Inactivated Bacterial Vaccine
1.3 Biological Inactivated Vaccine by Dosage Form
1.3.1 Global Biological Inactivated Vaccine Market Value Comparison by Dosage Form: 2024 VS 2031
1.3.2 Liquid Vaccines
1.3.3 Freeze-Dried Vaccines
1.4 Biological Inactivated Vaccine by Application
1.4.1 Global Biological Inactivated Vaccine Market Value by Application (2024 VS 2031)
1.4.2 Humans
1.4.3 Animals
1.5 Global Biological Inactivated Vaccine Market Size Estimates and Forecasts
1.5.1 Global Biological Inactivated Vaccine Revenue 2020-2031
1.5.2 Global Biological Inactivated Vaccine Sales 2020-2031
1.5.3 Global Biological Inactivated Vaccine Market Average Price (2020-2031)
1.6 Assumptions and Limitations
2 Biological Inactivated Vaccine Market Competition by Manufacturers
2.1 Global Biological Inactivated Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Biological Inactivated Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Biological Inactivated Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Biological Inactivated Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biological Inactivated Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biological Inactivated Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Biological Inactivated Vaccine, Date of Enter into This Industry
2.8 Global Biological Inactivated Vaccine Market Competitive Situation and Trends
2.8.1 Global Biological Inactivated Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Biological Inactivated Vaccine Players Market Share by Revenue
2.8.3 Global Biological Inactivated Vaccine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Biological Inactivated Vaccine Market Scenario by Region
3.1 Global Biological Inactivated Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Biological Inactivated Vaccine Sales by Region: 2020-2031
3.2.1 Global Biological Inactivated Vaccine Sales by Region: 2020-2025
3.2.2 Global Biological Inactivated Vaccine Sales by Region: 2026-2031
3.3 Global Biological Inactivated Vaccine Revenue by Region: 2020-2031
3.3.1 Global Biological Inactivated Vaccine Revenue by Region: 2020-2025
3.3.2 Global Biological Inactivated Vaccine Revenue by Region: 2026-2031
3.4 North America Biological Inactivated Vaccine Market Facts & Figures by Country
3.4.1 North America Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Biological Inactivated Vaccine Sales by Country (2020-2031)
3.4.3 North America Biological Inactivated Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biological Inactivated Vaccine Market Facts & Figures by Country
3.5.1 Europe Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Biological Inactivated Vaccine Sales by Country (2020-2031)
3.5.3 Europe Biological Inactivated Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biological Inactivated Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Biological Inactivated Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Biological Inactivated Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Biological Inactivated Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Biological Inactivated Vaccine Market Facts & Figures by Country
3.7.1 Latin America Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Biological Inactivated Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Biological Inactivated Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Biological Inactivated Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Biological Inactivated Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Biological Inactivated Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biological Inactivated Vaccine Sales by Type (2020-2031)
4.1.1 Global Biological Inactivated Vaccine Sales by Type (2020-2025)
4.1.2 Global Biological Inactivated Vaccine Sales by Type (2026-2031)
4.1.3 Global Biological Inactivated Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Biological Inactivated Vaccine Revenue by Type (2020-2031)
4.2.1 Global Biological Inactivated Vaccine Revenue by Type (2020-2025)
4.2.2 Global Biological Inactivated Vaccine Revenue by Type (2026-2031)
4.2.3 Global Biological Inactivated Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Biological Inactivated Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Biological Inactivated Vaccine Sales by Application (2020-2031)
5.1.1 Global Biological Inactivated Vaccine Sales by Application (2020-2025)
5.1.2 Global Biological Inactivated Vaccine Sales by Application (2026-2031)
5.1.3 Global Biological Inactivated Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Biological Inactivated Vaccine Revenue by Application (2020-2031)
5.2.1 Global Biological Inactivated Vaccine Revenue by Application (2020-2025)
5.2.2 Global Biological Inactivated Vaccine Revenue by Application (2026-2031)
5.2.3 Global Biological Inactivated Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Biological Inactivated Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Biological Inactivated Vaccine Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK Biological Inactivated Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck Biological Inactivated Vaccine Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Biological Inactivated Vaccine Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 SII
6.5.1 SII Company Information
6.5.2 SII Description and Business Overview
6.5.3 SII Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 SII Biological Inactivated Vaccine Product Portfolio
6.5.5 SII Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Company Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Valneva Biological Inactivated Vaccine Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Bharat Biotech
6.7.1 Bharat Biotech Company Information
6.7.2 Bharat Biotech Description and Business Overview
6.7.3 Bharat Biotech Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bharat Biotech Biological Inactivated Vaccine Product Portfolio
6.7.5 Bharat Biotech Recent Developments/Updates
6.8 KM Biologics
6.8.1 KM Biologics Company Information
6.8.2 KM Biologics Description and Business Overview
6.8.3 KM Biologics Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 KM Biologics Biological Inactivated Vaccine Product Portfolio
6.8.5 KM Biologics Recent Developments/Updates
6.9 Baxter
6.9.1 Baxter Company Information
6.9.2 Baxter Description and Business Overview
6.9.3 Baxter Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Baxter Biological Inactivated Vaccine Product Portfolio
6.9.5 Baxter Recent Developments/Updates
6.10 Bio Farma
6.10.1 Bio Farma Company Information
6.10.2 Bio Farma Description and Business Overview
6.10.3 Bio Farma Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bio Farma Biological Inactivated Vaccine Product Portfolio
6.10.5 Bio Farma Recent Developments/Updates
6.11 IVAC
6.11.1 IVAC Company Information
6.11.2 IVAC Description and Business Overview
6.11.3 IVAC Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 IVAC Biological Inactivated Vaccine Product Portfolio
6.11.5 IVAC Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Company Information
6.12.2 Takeda Description and Business Overview
6.12.3 Takeda Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Takeda Biological Inactivated Vaccine Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 Emergent BioSolutions
6.13.1 Emergent BioSolutions Company Information
6.13.2 Emergent BioSolutions Description and Business Overview
6.13.3 Emergent BioSolutions Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Emergent BioSolutions Biological Inactivated Vaccine Product Portfolio
6.13.5 Emergent BioSolutions Recent Developments/Updates
6.14 Sinergium Biotech
6.14.1 Sinergium Biotech Company Information
6.14.2 Sinergium Biotech Description and Business Overview
6.14.3 Sinergium Biotech Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Sinergium Biotech Biological Inactivated Vaccine Product Portfolio
6.14.5 Sinergium Biotech Recent Developments/Updates
6.15 China Biotechnology
6.15.1 China Biotechnology Company Information
6.15.2 China Biotechnology Description and Business Overview
6.15.3 China Biotechnology Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 China Biotechnology Biological Inactivated Vaccine Product Portfolio
6.15.5 China Biotechnology Recent Developments/Updates
6.16 Sinovac
6.16.1 Sinovac Company Information
6.16.2 Sinovac Description and Business Overview
6.16.3 Sinovac Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Sinovac Biological Inactivated Vaccine Product Portfolio
6.16.5 Sinovac Recent Developments/Updates
6.17 Kangtai Biological
6.17.1 Kangtai Biological Company Information
6.17.2 Kangtai Biological Description and Business Overview
6.17.3 Kangtai Biological Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Kangtai Biological Biological Inactivated Vaccine Product Portfolio
6.17.5 Kangtai Biological Recent Developments/Updates
6.18 Zhifei Biological
6.18.1 Zhifei Biological Company Information
6.18.2 Zhifei Biological Description and Business Overview
6.18.3 Zhifei Biological Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Zhifei Biological Biological Inactivated Vaccine Product Portfolio
6.18.5 Zhifei Biological Recent Developments/Updates
6.19 AIM Vaccine
6.19.1 AIM Vaccine Company Information
6.19.2 AIM Vaccine Description and Business Overview
6.19.3 AIM Vaccine Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.19.4 AIM Vaccine Biological Inactivated Vaccine Product Portfolio
6.19.5 AIM Vaccine Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biological Inactivated Vaccine Industry Chain Analysis
7.2 Biological Inactivated Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biological Inactivated Vaccine Production Mode & Process Analysis
7.4 Biological Inactivated Vaccine Sales and Marketing
7.4.1 Biological Inactivated Vaccine Sales Channels
7.4.2 Biological Inactivated Vaccine Distributors
7.5 Biological Inactivated Vaccine Customer Analysis
8 Biological Inactivated Vaccine Market Dynamics
8.1 Biological Inactivated Vaccine Industry Trends
8.2 Biological Inactivated Vaccine Market Drivers
8.3 Biological Inactivated Vaccine Market Challenges
8.4 Biological Inactivated Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Biological Inactivated Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Biological Inactivated Vaccine Market Value by Dosage Form, (US$ Million) & (2024 VS 2031)
Table 3. Global Biological Inactivated Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
Table 4. Global Biological Inactivated Vaccine Market Competitive Situation by Manufacturers in 2024
Table 5. Global Biological Inactivated Vaccine Sales (K Units) of Key Manufacturers (2020-2025)
Table 6. Global Biological Inactivated Vaccine Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Biological Inactivated Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
Table 8. Global Biological Inactivated Vaccine Revenue Share by Manufacturers (2020-2025)
Table 9. Global Market Biological Inactivated Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 10. Global Key Players of Biological Inactivated Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 11. Global Key Manufacturers of Biological Inactivated Vaccine, Manufacturing Sites & Headquarters
Table 12. Global Key Manufacturers of Biological Inactivated Vaccine, Product Type & Application
Table 13. Global Key Manufacturers of Biological Inactivated Vaccine, Date of Enter into This Industry
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Biological Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Inactivated Vaccine as of 2024)
Table 16. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 17. Global Biological Inactivated Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 18. Global Biological Inactivated Vaccine Sales by Region (2020-2025) & (K Units)
Table 19. Global Biological Inactivated Vaccine Sales Market Share by Region (2020-2025)
Table 20. Global Biological Inactivated Vaccine Sales by Region (2026-2031) & (K Units)
Table 21. Global Biological Inactivated Vaccine Sales Market Share by Region (2026-2031)
Table 22. Global Biological Inactivated Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 23. Global Biological Inactivated Vaccine Revenue Market Share by Region (2020-2025)
Table 24. Global Biological Inactivated Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 25. Global Biological Inactivated Vaccine Revenue Market Share by Region (2026-2031)
Table 26. North America Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 27. North America Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)
Table 28. North America Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)
Table 29. North America Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 30. North America Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 31. Europe Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 32. Europe Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)
Table 33. Europe Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)
Table 34. Europe Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 35. Europe Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 36. Asia Pacific Biological Inactivated Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 37. Asia Pacific Biological Inactivated Vaccine Sales by Region (2020-2025) & (K Units)
Table 38. Asia Pacific Biological Inactivated Vaccine Sales by Region (2026-2031) & (K Units)
Table 39. Asia Pacific Biological Inactivated Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 40. Asia Pacific Biological Inactivated Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 41. Latin America Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 42. Latin America Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)
Table 43. Latin America Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)
Table 44. Latin America Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 45. Latin America Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 46. Middle East and Africa Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 47. Middle East and Africa Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)
Table 48. Middle East and Africa Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)
Table 49. Middle East and Africa Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 50. Middle East and Africa Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 51. Global Biological Inactivated Vaccine Sales (K Units) by Type (2020-2025)
Table 52. Global Biological Inactivated Vaccine Sales (K Units) by Type (2026-2031)
Table 53. Global Biological Inactivated Vaccine Sales Market Share by Type (2020-2025)
Table 54. Global Biological Inactivated Vaccine Sales Market Share by Type (2026-2031)
Table 55. Global Biological Inactivated Vaccine Revenue (US$ Million) by Type (2020-2025)
Table 56. Global Biological Inactivated Vaccine Revenue (US$ Million) by Type (2026-2031)
Table 57. Global Biological Inactivated Vaccine Revenue Market Share by Type (2020-2025)
Table 58. Global Biological Inactivated Vaccine Revenue Market Share by Type (2026-2031)
Table 59. Global Biological Inactivated Vaccine Price (US$/Unit) by Type (2020-2025)
Table 60. Global Biological Inactivated Vaccine Price (US$/Unit) by Type (2026-2031)
Table 61. Global Biological Inactivated Vaccine Sales (K Units) by Application (2020-2025)
Table 62. Global Biological Inactivated Vaccine Sales (K Units) by Application (2026-2031)
Table 63. Global Biological Inactivated Vaccine Sales Market Share by Application (2020-2025)
Table 64. Global Biological Inactivated Vaccine Sales Market Share by Application (2026-2031)
Table 65. Global Biological Inactivated Vaccine Revenue (US$ Million) by Application (2020-2025)
Table 66. Global Biological Inactivated Vaccine Revenue (US$ Million) by Application (2026-2031)
Table 67. Global Biological Inactivated Vaccine Revenue Market Share by Application (2020-2025)
Table 68. Global Biological Inactivated Vaccine Revenue Market Share by Application (2026-2031)
Table 69. Global Biological Inactivated Vaccine Price (US$/Unit) by Application (2020-2025)
Table 70. Global Biological Inactivated Vaccine Price (US$/Unit) by Application (2026-2031)
Table 71. Sanofi Company Information
Table 72. Sanofi Description and Business Overview
Table 73. Sanofi Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 74. Sanofi Biological Inactivated Vaccine Product
Table 75. Sanofi Recent Developments/Updates
Table 76. GSK Company Information
Table 77. GSK Description and Business Overview
Table 78. GSK Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 79. GSK Biological Inactivated Vaccine Product
Table 80. GSK Recent Developments/Updates
Table 81. Merck Company Information
Table 82. Merck Description and Business Overview
Table 83. Merck Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 84. Merck Biological Inactivated Vaccine Product
Table 85. Merck Recent Developments/Updates
Table 86. Pfizer Company Information
Table 87. Pfizer Description and Business Overview
Table 88. Pfizer Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 89. Pfizer Biological Inactivated Vaccine Product
Table 90. Pfizer Recent Developments/Updates
Table 91. SII Company Information
Table 92. SII Description and Business Overview
Table 93. SII Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 94. SII Biological Inactivated Vaccine Product
Table 95. SII Recent Developments/Updates
Table 96. Valneva Company Information
Table 97. Valneva Description and Business Overview
Table 98. Valneva Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Valneva Biological Inactivated Vaccine Product
Table 100. Valneva Recent Developments/Updates
Table 101. Bharat Biotech Company Information
Table 102. Bharat Biotech Description and Business Overview
Table 103. Bharat Biotech Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Bharat Biotech Biological Inactivated Vaccine Product
Table 105. Bharat Biotech Recent Developments/Updates
Table 106. KM Biologics Company Information
Table 107. KM Biologics Description and Business Overview
Table 108. KM Biologics Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. KM Biologics Biological Inactivated Vaccine Product
Table 110. KM Biologics Recent Developments/Updates
Table 111. Baxter Company Information
Table 112. Baxter Description and Business Overview
Table 113. Baxter Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Baxter Biological Inactivated Vaccine Product
Table 115. Baxter Recent Developments/Updates
Table 116. Bio Farma Company Information
Table 117. Bio Farma Description and Business Overview
Table 118. Bio Farma Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Bio Farma Biological Inactivated Vaccine Product
Table 120. Bio Farma Recent Developments/Updates
Table 121. IVAC Company Information
Table 122. IVAC Description and Business Overview
Table 123. IVAC Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. IVAC Biological Inactivated Vaccine Product
Table 125. IVAC Recent Developments/Updates
Table 126. Takeda Company Information
Table 127. Takeda Description and Business Overview
Table 128. Takeda Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Takeda Biological Inactivated Vaccine Product
Table 130. Takeda Recent Developments/Updates
Table 131. Emergent BioSolutions Company Information
Table 132. Emergent BioSolutions Description and Business Overview
Table 133. Emergent BioSolutions Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Emergent BioSolutions Biological Inactivated Vaccine Product
Table 135. Emergent BioSolutions Recent Developments/Updates
Table 136. Sinergium Biotech Company Information
Table 137. Sinergium Biotech Description and Business Overview
Table 138. Sinergium Biotech Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Sinergium Biotech Biological Inactivated Vaccine Product
Table 140. Sinergium Biotech Recent Developments/Updates
Table 141. China Biotechnology Company Information
Table 142. China Biotechnology Description and Business Overview
Table 143. China Biotechnology Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. China Biotechnology Biological Inactivated Vaccine Product
Table 145. China Biotechnology Recent Developments/Updates
Table 146. Sinovac Company Information
Table 147. Sinovac Description and Business Overview
Table 148. Sinovac Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Sinovac Biological Inactivated Vaccine Product
Table 150. Sinovac Recent Developments/Updates
Table 151. Kangtai Biological Company Information
Table 152. Kangtai Biological Description and Business Overview
Table 153. Kangtai Biological Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Kangtai Biological Biological Inactivated Vaccine Product
Table 155. Kangtai Biological Recent Developments/Updates
Table 156. Zhifei Biological Company Information
Table 157. Zhifei Biological Description and Business Overview
Table 158. Zhifei Biological Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Zhifei Biological Biological Inactivated Vaccine Product
Table 160. Zhifei Biological Recent Developments/Updates
Table 161. AIM Vaccine Company Information
Table 162. AIM Vaccine Description and Business Overview
Table 163. AIM Vaccine Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 164. AIM Vaccine Biological Inactivated Vaccine Product
Table 165. AIM Vaccine Recent Developments/Updates
Table 166. Key Raw Materials Lists
Table 167. Raw Materials Key Suppliers Lists
Table 168. Biological Inactivated Vaccine Distributors List
Table 169. Biological Inactivated Vaccine Customers List
Table 170. Biological Inactivated Vaccine Market Trends
Table 171. Biological Inactivated Vaccine Market Drivers
Table 172. Biological Inactivated Vaccine Market Challenges
Table 173. Biological Inactivated Vaccine Market Restraints
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
Table 177. Authors List of This Report
List of Figures
Figure 1. Product Picture of Biological Inactivated Vaccine
Figure 2. Global Biological Inactivated Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Biological Inactivated Vaccine Market Share by Type: 2024 & 2031
Figure 4. Inactivated Virus Vaccine Product Picture
Figure 5. Inactivated Bacterial Vaccine Product Picture
Figure 6. Global Biological Inactivated Vaccine Market Value by Dosage Form, (US$ Million) & (2020-2031)
Figure 7. Global Biological Inactivated Vaccine Market Share by Dosage Form: 2024 VS 2031
Figure 8. Liquid Vaccines Product Picture
Figure 9. Freeze-Dried Vaccines Product Picture
Figure 10. Global Biological Inactivated Vaccine Market Value by Application (2020-2031) & (US$ Million)
Figure 11. Global Biological Inactivated Vaccine Market Share by Application: 2024 & 2031
Figure 12. Humans
Figure 13. Animals
Figure 14. Global Biological Inactivated Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Biological Inactivated Vaccine Market Size (2020-2031) & (US$ Million)
Figure 16. Global Biological Inactivated Vaccine Sales (2020-2031) & (K Units)
Figure 17. Global Biological Inactivated Vaccine Average Price (US$/Unit) & (2020-2031)
Figure 18. Biological Inactivated Vaccine Report Years Considered
Figure 19. Biological Inactivated Vaccine Sales Share by Manufacturers in 2024
Figure 20. Global Biological Inactivated Vaccine Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Biological Inactivated Vaccine Players: Market Share by Revenue in Biological Inactivated Vaccine in 2024
Figure 22. Biological Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Biological Inactivated Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)
Figure 25. North America Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)
Figure 26. United States Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)
Figure 29. Europe Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)
Figure 30. Germany Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Biological Inactivated Vaccine Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Biological Inactivated Vaccine Revenue Market Share by Region (2020-2031)
Figure 37. China Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. China Taiwan Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)
Figure 45. Latin America Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Colombia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Biological Inactivated Vaccine by Type (2020-2031)
Figure 56. Global Revenue Market Share of Biological Inactivated Vaccine by Type (2020-2031)
Figure 57. Global Biological Inactivated Vaccine Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Biological Inactivated Vaccine by Application (2020-2031)
Figure 59. Global Revenue Market Share of Biological Inactivated Vaccine by Application (2020-2031)
Figure 60. Global Biological Inactivated Vaccine Price (US$/Unit) by Application (2020-2031)
Figure 61. Biological Inactivated Vaccine Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
